MRNA is down 0.62% today in the Healthcare sector. Volume is 17.05M vs a 30-day average of 18.59M (0.92x).
Moderna Inc. is scheduled to report earnings Fri, Nov 6, 2026 · before open. Analysts expect EPS of $-1.28 on revenue of about $902.75M. Stocks often move sharply on earnings day.
Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data for their individualized mRNA melanoma vaccine plus KEYTRUDA, intismeran, at ESMO 2026. The Phase 3 trial showed a…
Moderna’s stock tanked Thursday following a data leak for the drugmaker’s cancer-vaccine candidate, which is co-developed with Merck.
Key TakeawaysModerna shares fell another 8% this morning. On Saturday it and its partner Merck presented full Phase 3 data showing their personalized melanoma vaccine cut the risk…
2026-10-26. The following slide deck was published by Moderna, Inc.
Moderna’s stock has taken a big hit that might signal the end of this year’s cancer vaccine-driven rally. It may not, however, be too late to play the forces behind its rise.